An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
The FDA has proposed taking semaglutide, tirzepatide, and liraglutide off a federal list that allows compounding pharmacies to buy large batches of those drugs and make customized doses. In plain terms, the agency wants to stop pharmacies that mix medicines on demand from using bulk supplies of these specific weight-loss and diabetes drugs. This is a proposal — not a final rule yet — and it affects how some patients might get these medicines through compounding pharmacies. Semaglutide, tirzepatide, and liraglutide are prescription drugs used mainly for type 2 diabetes and, more recently, for weight loss. Semaglutide is the active ingredient in brands like Ozempic and Wegovy; it acts like a gut hormone that signals fullness and slows stomach emptying. Tirzepatide is newer and targets two of those gut-hormone pathways at once, which can lead to bigger weight-loss effects in studies. Liraglutide is an older drug in the same family. All three are made and sold by drug companies in fixed formulations that were tested for safety and effectiveness. The FDA’s move is about compounding law. A 503B bulk list currently allows outsourcing pharmacies to buy certain active ingredients in bulk and make patient-specific formulations without going through the full drug-approval process for each preparation. By proposing to exclude these three drugs, the FDA is saying they shouldn’t be on that list anymore. The agency has cited concerns that compounding from bulk for widely-used, approved drugs can bypass the normal manufacturing safeguards and may harm patients. The announcement doesn’t change how the original branded or generic versions are prescribed or sold through regular pharmacies or clinics. Why this matters is practical. These drugs are in high demand right now for weight loss and diabetes, and supply issues and price have pushed some patients to seek compounded versions that can be cheaper or come in alternative doses. If the FDA finalizes this change, compounding pharmacies would face limits in making alternative versions from bulk supplies, which could reduce availability of nonstandard doses or forms some prescribers have used. For most people getting medicine directly from a doctor or a regular pharmacy-prescribed brand, nothing changes. But people relying on compounded versions — often to cut costs or get specific doses — could be affected. There are important caveats. The proposal is about compounding rules, not about saying these drugs are unsafe overall. The FDA’s goal is to protect patients from medicines made outside of the manufacturer’s controlled processes. Compounded drugs can carry extra risks like variable potency, contamination, or incorrect dosing. At the same time, some patients and pharmacies argue compounding fills gaps when commercially made products aren’t available in the needed form. This is not a final ban yet; the FDA will take public comments and could adjust the plan. If you use one of these medicines and are concerned about access or cost, talk to your healthcare provider before making any changes. Bottom line: The FDA wants to stop compounding pharmacies from using bulk supplies of semaglutide, tirzepatide, and liraglutide to make custom versions, which could reduce the availability of compounded alternatives but doesn’t affect the approved brand-name or generic products themselves.
Source: Moomoo